In coordination with these findings, rifaximin, a semi-systemic rifamycin-derived antibiotic, as an intestine-specific human PXR agonist, also represses NF-κB signaling and displays a preventive and therapeutic role for the IBD model 85. This evidence concerns the gene NR1I2 and inflammatory bowel disease.